The minds behind ArcticZymes Technologies
We, at ArcticZymes Technologies, are aware of the critical role enzymes play in research, diagnostics and therapeutics. This understanding drives our team of highly dedicated scientists and experienced managers to work with passion and dedication at the highest level to exceed the expectations of our partners.
The management team
Dr. Jethro Holter, CEO
Dr Jethro Holter (born 1972) joined ArcticZymes as Managing Director on January 1st, 2015 and was appointed interim CEO on October 23rd 2019 and then became permanent CEO on 22nd April, 2020. He has previous experience from Life Technologies (Thermo Fisher Scientific) in international business development of B2B/OEM solutions with Diagnostic and Life Science companies as well as other commercial experience. Earlier in his career, he was R&D Director at Mole Genetics AS developing automated sample prep solutions. Jethro Holter holds a Ph.D in Molecular Neuroscience from Cardiff University, UK. Number of shares in ArcticZymes Technologies held by Dr Holter: 80,564. Number of options in ArcticZymes Technologies held by Dr Holter: 270,000
Børge Sørvoll, CFO
Børge Sørvoll (born 1975) assumed the position as CFO on Oct 1, 2014. He has previous experience from the position as SCM Manager at Subsea 7, and before that as CFO in Front Exploration and as Managing Director of Troms Kraft Invest. Børge holds a "Siviløkonom" degree in Finance from the University of Wyoming. Number of shares in ArcticZymes Technologies held by Mr. Sørvoll: 25,428. Number of options in ArcticZymes Technologies held by Mr. Sørvoll: 380,000
Dr. Olav Lanes, VP R&D and Applications
Dr Lanes (born 1972) was granted a Dr Scient degree in molecular biology from University of Tromsø in 2000. He joined the company (Biotec Pharmacon) as a researcher the same year and the position as Director of R&D and Applications since in 2016. Olav has extensive experience in innovation management and product development. Dr. Lanes is inventor and co-inventor of eight patent- or pending patent families, all today part of the IPR assets in the company. Number of shares in ArcticZymes Technologies held by Dr Lanes: 2000. Number of options in ArcticZymes Technologies held by Dr Lanes: 100,000.
Dirk Hahneiser, VP of Business Development and Marketing
Dirk Hahneiser (born 1968) joined ArcticZymes in 2022 as VP of Business Development and Marketing. He brings with him a wealth of commercial and marketing experience from Johnson & Johnson, Ecolab and Thermo Fisher Scientific. Prior to joining ArcticZymes, Dirk was the Head of Sales for the OEM Laboratory Products Business at Thermo Fisher Scientific, Director of Commercial Operations and Key Accounts at Ecolab and Business Unit Director at Johnson & Johnson. He holds a Master's of International Business and a B.S. Degree in Management from the Darla Moore School of Business at the University of South Carolina. Number of shares in ArcticZymes Technologies held by Mr. Hahneiser: 150. Number of options in ArcticZymes Technologies held by Mr. Hahneiser: 0.
Dr. Marit Sjo Lorentzen, VP Operations
Dr Lorentzen (born 1968) was granted a Dr Scient degree in Biotechnology from University of Tromsø in 2005. She joined the company (Biotec Pharmacon) as a Sr. Research Scientist in 2011 and holds the position as Director of Operations since 2020. She has extensive work experience within laboratory operations, management and research. She is employee elected to The Board of Directors in ArcticZymes Technologies. Number of shares in ArcticZymes Technologies held by Dr Lorentzen: 20,331. Number of options in ArcticZymes Technologies held by Dr Lorentzen: 115,000.
Dr. Darren Ellis, CSO
Dr Darren Ellis (born 1972) joined ArcticZymes as CSO on December 1st, 2022. Prior to the appointment, he worked as an independent consultant setting up the company’s site at Oslo Science Park during 2021-2022. Darren has extensive industry R&D experience from Thermo Fisher Scientific acting as Sr. R&D Manager/Program Manager and Sr. Product Manager developing technology and solutions linked to the Licensing and Commercial Supply division to drive OEM/B2B sales to major global diagnostics companies. Specifically, he developed solutions for automated viral diagnostics and worked as product manager for Dynabeads M280 used in more than 1 billion human IVD tests per year. Earlier in his career, he was one of the original scientific team at Solexa Ltd. developing ‘next-generation sequencing’ technology. Solexa was later acquired by Illumina and the technology further commercialised to become the market dominant NGS system. Darren holds a PhD in Molecular & Cell Biology from the University of Dundee, and BSc (Hons) in Chemistry from the University of York. He did his postdoctoral work at Dept. of Pharmacology, University of Cambridge, and holds several patents relating to functional immobilization of biomolecules and nucleic acid sample preparation.
Number of shares in ArcticZymes Technologies held by Mr. Ellis: 0 . Number of options in ArcticZymes Technologies held by Mr. Ellis: 100.000
The board of directors
Dr. Marie Ann Roskrow, Chairman
Dr. Roskrow gained a BSc (Hons), MBBS (Hons) degree and a PhD in Immunology from the University of London. She has more than 25 years of experience as a physician / medical researcher, investment banker, CEO and chairperson in both private and listed companies such as the GSF Research Institute (Munich), Patrys Ltd (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney). During her 8 years at Lazard, Marie executed a wide-range of complex strategic transactions including: mergers and acquisitions, joint ventures and asset divestitures. Additionally she was involved in the execution of > 50 financing deals including: IPOs, capital raisings and structured debt. Number of shares in ArcticZymes Technologies held by Dr. Roskrow: 0. Number of options in ArcticZymes Technologies held by Dr. Roskrow: 200,000
Jane Theaker, Director
Jane Theaker has a BSc (Hons) in Biochemistry from Manchester University and an MSc in Biomedical Science from Manchester Metropolitan University. She has over 25 years experience in Diagnostics and Pharma, having co-invented a technology that was later spun out to create DxS which was acquired by QIAGEN in 2009 for $130M. She trained in the NHS and worked at Astrazeneca evaluating novel genetic technologies for drug discovery and development. At QIAGEN she lead a team of scientists who were responsible for the successful delivery of several FDA approved companion diagnostic products and went on to head up the technology office, with technology horizon-scanning responsibilities. Jane went on to become VP of Genomics at LGC (the Laboratory of the Government Chemist) in 2015. Jane is currently CEO of PBD Biotech Ltd. Number of shares in ArcticZymes Technologies held by Mrs. Theaker: 10.044. Number of options in ArcticZymes Technologies held by Mrs. Theaker: 0
Dr. Bernd Striberny, Director - employee elected
Dr. Striberny holds a Diploma degree in Biology from the University of Kiel in Germany and a PhD in Molecular Biology from the Arctic University of Norway, Tromsø, Norway. Bernd has extensive work experience in biodiscovery of novel enzymes and molecular biology techniques. In his position as a Research Manager his responsibilities at ArcticZymes Technologies lie within personnel management, research, biodiscovery and development of new enzyme prototypes. Number of shares in ArcticZymes Technologies held by Dr. Striberny: 200. Number of options in ArcticZymes Technologies held by Dr Striberny: 0
Lill-Hege Henriksen, Observer – employee elected
Lill Hege Henriksen holds a chemist engineering degree in Biotechnology from Høgskolen in Nord-Trøndelag, a Cand.mag degree from the University of Tromsø and an MBA from the University of Nordland in Bodø.
She worked in several laboratories at the University of Tromsø and University hospital before joining ArcticZymes in 2011, while finishing the MBA master’s degree. In 2012, she started full time in the marketing and sales department. She has been doing all order handling in ArcticZymes the last 10 years and know customers well. Number of shares in ArcticZymes Technologies held by Mrs. Henriksen: 3,088. Number of options in ArcticZymes Technologies held by Mrs. Henriksen: 0
